{
    "relation": [
        [
            "Arms",
            "Experimental: Group 5 Dose 5 of subcutaneous evolocumab (AMG 145)",
            "Placebo Comparator: Group 9 Subcutaneous placebo",
            "Experimental: Group 6 Dose 6 of subcutaneous evolocumab (AMG 145)",
            "Experimental: Group 4 Dose 4 of subcutaneous evolocumab (AMG 145)",
            "Experimental: Group 3 Dose 3 of subcutaneous evolocumab (AMG 145)",
            "Experimental: Group 2 Dose 2 of subcutaneous evolocumab (AMG 145)",
            "Active Comparator: Group 7 Oral Ezetimibe",
            "Placebo Comparator: Group 8 Subcutaneous placebo",
            "Experimental: Group 1 Dose 1 of subcutaneous evolocumab (AMG 145)"
        ],
        [
            "Assigned Interventions",
            "Biological: evolocumab (AMG 145) Patients will receive evolocumab (AMG 145) every 2 or 4 weeks",
            "Other: Placebo Patients will receive Placebo every 2 weeks or 4 weeks. All patients at screening will participate in the placebo run-in.",
            "Biological: evolocumab (AMG 145) Patients will receive evolocumab (AMG 145) every 2 or 4 weeks",
            "Biological: evolocumab (AMG 145) Patients will receive evolocumab (AMG 145) every 2 or 4 weeks",
            "Biological: evolocumab (AMG 145) Patients will receive evolocumab (AMG 145) every 2 or 4 weeks",
            "Biological: evolocumab (AMG 145) Patients will receive evolocumab (AMG 145) every 2 or 4 weeks",
            "Drug: Ezetimibe Patients will take Ezetimibe daily",
            "Other: Placebo Patients will receive Placebo every 2 weeks or 4 weeks. All patients at screening will participate in the placebo run-in.",
            "Biological: evolocumab (AMG 145) Patients will receive evolocumab (AMG 145) every 2 or 4 weeks"
        ]
    ],
    "pageTitle": "Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/show/NCT01375777",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989234.2/warc/CC-MAIN-20150728002309-00227-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 865472547,
    "recordOffset": 865456153,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "March 2012 (Final data collection date for primary outcome measure) Primary Completion Date: March 2012 Study Completion Date: June 2011 Study Start Date: 411 Enrollment: Percent change from baseline in apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratio after 12 weeks of treatment [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Percent change from baseline in the total cholesterol/high density lipoprotein cholesterol (HDL-C) ratio after 12 weeks of treatment [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Percent change from baseline in apolipoprotein B (ApoB) after 12 weeks of treatment [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Percent change from baseline in non-high density lipoprotein cholesterol (non-HDL-C) after 12 weeks of treatment [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) after 12 weeks of treatment [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Secondary Outcome Measures: Percent change from baseline in low density lipoprotein cholesterol (LDL-C) after 12 weeks of treatment [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Primary Outcome Measures:",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 18 Years to 75 Years Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion Criteria: Male or female \u2265 18 to \u2264 75 years of age Low density lipoprotein cholesterol (LDL-C) \u2265 100 mg/dL and < 190 mg/dL Framingham risk score of 10% or less Fasting triglycerides < 400 mg/dL Exclusion Criteria: History of coronary heart disease NYHA II - IV heart failure Uncontrolled cardiac arrhythmia Uncontrolled hypertension \u00a0 Contacts and Locations Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}